Nonnucleoside reverse transcriptase inhibitor (NNRTI). Prepn: S. D. Young et al., EP 582455; eidem, US 5519021 (1994, 1996 both to Merck & Co.). Pharmacology: S. D. Young et al., Antimicrob. Agents Chemother. 39, 2602 (1995). Enantioselective synthesis: A. S. Thompson et al., Tetrahedron Lett. 36, 8937 (1995). Total synthesis and resolution of enantiomers: L. A. Radesca et al., Synth. Commun. 27, 4373 (1997). Ionization behavior: S. R. Rabel et al., Pharm. Dev. Technol. 1, 91 (1996). Clinical trial as component of combination therapy in HIV-1 infection in adults: S. Staszewski et al., N. Engl. J. Med. 341, 1865 (1999); in children: S. E. Starr et al., ibid. 1874. Review of clinical experience: C. Fortin, V. Joly, Expert Rev. Anti Infect. Ther. 2, 671-684 (2004).
Antiretroviral.
Reverse Transcriptase Inhibitor; Antiretroviral; Reverse Transcriptase Inhibitors; Nonnucleosides